In a Jan. 2 research note, analyst Yasmeen Rahimi reported that Allena Pharmaceuticals Inc. (ALNA:NASDAQ) recently initiated its URIROX-2 trial evaluating reloxaliase (ALLN-177) in patients with enteric hyperoxaluria after it reached agreement with the FDA on the study design and the biologics license application submission plan.
"Especially with the full Phase 3 program underway and shares undervalued in our opinion, we believe this is a buying opportunity" for Allena, Rahimi added. In fact, ROTH's $61 per share price target on this company reflects a potential nearly tenbagger return as the stock is currently trading at around $6.46 per share.
ROTH anticipates 2019 will be transformative for Allena, with numerous catalysts expected to occur, each of which should present a buying opportunity. These events include interim clinical data in H1/19 from the Phase 2 basket trial study; topline results in H2/19 from URIROX-1 and from study 206; and filing of an investigational new drug application for ALLN-346 in gout, which presents in chronic kidney disease patients, sometime this year.
In its discussions with the FDA on URIROX-2, Allena "got what it wanted" in terms of trial design, Rahimi noted. The primary endpoint will be the percent difference from the baseline reading in 24-hour urate oxidase measured during weeks one through four and 16 to 24.
"We believe this morning's announcement of the FDA's agreement with these key design and approval strategy elements represent a big win for Allena," wrote the analyst.
[NLINSERT]Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from ROTH Capital Partners, Allena Pharmaceuticals Inc., Company Note, January 2, 2019
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
ROTH makes a market in shares of Allena Pharmaceuticals, Inc. and as such, buys and sells from customers on a principal basis.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.
